ATS 2024 Final Program

Click on the session title to view the speakers

217

MONDAY • MAY 20

407 Prevalence of TP53 Mutated Airway Epithelial Cell Colonies Is Inversely Proportional to Colony Size 408 Reconstruction of Multiple Single Cell RNA Sequencing Datasets Provide New Insights of Immune Cell Interaction in Both Murine and Human Lung Adenocarcinoma 409 Identification of Tumor-suppressive MicroRNAs and Their Targets Oncogenes in Small Cell Lung Cancer 410 Endothelial UBE2M Promotes Tumor Angiogenesis Through DLL4 411 Immunomodulatory Mechanisms of ACT001 in Non-small Cell Lung Cancer: Targeting PD-L1 and Restoring T-cell Function 413 Targeting AXL-MARCKS Interaction in Macrophages Enhances Lung Cancer Immunotherapy Response 414 Evaluating the Diagnostic Potential of Circulating Exosomal Circular RNAs in Non-small-cell Lung Cancer: A Diagnostic Accuracy Meta-analysis 415 Lipidome Abnormalities of BAL Fluid in Non-Small Cell Lung Cancer 416 Identification of Therapeutic Target Molecules for Lung Adenocarcinoma Based on MicroRNA Analysis 417 Utility of Cytology Smears of Bronchoscopic Specimens for DNA/RNA Extraction in Patients With Non-small Cell Lung Cancer 418 Early Diagnosis of Lung Cancer by Detecting Tumor Originated Deoxyribo Nucleic Acid (DNA) Fragments Using Plasma Cell-free DNA Methylome and Fragmentome Profiles 419 The Polymerase Epsilon Gene Expression and Mutation Predictive Significance in Patients Receiving Immune Checkpoint Inhibitors (icis) for Non-small Cell Lung Cancer (NSCLS) 420 Pneumonitis Induced by Immune Checkpoint Inhibitors in Combination With Cytotoxic Chemotherapy in Patients With Preexisting Interstitial Lung Diseases: A Retrospective Study 421 Efficacy and Safety of First-line Immunotherapy Plus Chemotherapy in Treating Elderly Patients With Extensive-stage Small Cell Lung Cancer 422 Radiation Pneumonitis in Lung Cancer Patients: Comorbidities and Risk Factors

423 Treatment Outcome and Safety of Durvalumab After Concurrent Chemoradiotherapy in Elderly Patients With Unresectable Stage III Non-Small Cell Lung Cancer 424 Diagnostic Yield and Synergistic Impact of Needle Aspiration and Forceps Biopsy With Electromagnetic Navigation Bronchoscopy for Pulmonary Lesions: A Randomized Trial 425 Integrating Proteomes of Tumor and Bronchoalveolar Lavage Fluid (BALF) Reveal Aberrant RNA Binding Protein for Early-stage Lung Adenocarcinoma Diagnosis

BEHAVIORAL • CLINICAL RAPID POSTER DISCUSSION SESSION

B110 ADVANCES IN PRECISION

APPROACHES TO DETECTION AND TREATMENT OF EARLY LUNG CANCER

2:15 p.m. - 4:15 p.m.

San Diego Convention Center Room 28C-E (Upper Level)

Viewing/Discussion Abstract Summaries

2:15-3:00 3:00-4:15

301 Lung Cancer Screening Eligibility Among Asian-american Individuals Diagnosed With Lung Cancer 302 Extent and Determinants of Racial and Ethnic Disparities in the Opportunity to Undergo Lung Cancer Screening 303 Elevated BMI Predicts Poor Lung Cancer Screening Outcomes Independent of Diabetes Mellitus in a National Lung Screening Trial Subgroup (n=18,463) 304 Comorbidity and Frailty in Patients Undergoing Lung Cancer Screening 305 Longitudinal Adherence to Recommended Lung Cancer Screening Follow-up: A Multicenter Cohort Study 306 How Menthol Use Complicates Lung Cancer Screening Eligibility 307 Added Value of Visual Emphysema in Lung-RADS Categorization

ATS 2024 Conference Program • San Diego, CA